| Literature DB >> 27495233 |
Alfredo Conti1, Sara G Romeo2, Annamaria Cama2, Domenico La Torre2, Valeria Barresi3, Gaetana Pezzino3, Chiara Tomasello3, Salvatore Cardali2, Filippo F Angileri2, Francesca Polito4, Guido Ferlazzo3, Rosamaria Di Giorgio4, Antonino Germanò2, M'hammed Aguennouz4.
Abstract
The role of microRNAs (miRNAs) in glioma biology is increasingly recognized. To investigate the regulatory mechanisms governing the malignant signature of gliomas with different grades of malignancy, we analyzed miRNA expression profiles in human grade I-IV tumor samples and primary glioma cell cultures. Multiplex real-time PCR was used to profile miRNA expression in a set of World Health Organization (WHO) grade I (pilocytic astrocytoma), II (diffuse fibrillary astrocytoma), and IV (glioblastoma multiforme) astrocytic tumors and primary glioma cell cultures. Primary glioma cell cultures were used to evaluate the effect of transfection of specific miRNAs and miRNA inhibitors. miRNA microarray showed that a set of miRNAs was consistently upregulated in all glioma samples. miR-363 was upregulated in all tumor specimens and cell lines, and its expression correlated with tumor grading. The transfection of glioma cells with the specific inhibitor of miR-363 increased the expression level of tumor suppressor growth-associated protein 43 (GAP-43). Transfection of miR-363 induced cell survival, while inhibition of miR-363 significantly reduced glioma cell viability. Furthermore, miRNA-363 inhibition induced the downregulation of AKT, cyclin-D1, matrix metalloproteinase (MMP)-2, MMP-9, and Bcl-2 and upregulation of caspase 3. Together, these data suggest that the upregulation of miR-363 may play a role in malignant glioma signature.Entities:
Keywords: Astrocytoma; Gap-43; Glioblastoma multiforme; miRNA microarray; miRNA-363
Mesh:
Substances:
Year: 2016 PMID: 27495233 DOI: 10.1007/s13277-016-5273-x
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283